How stress changes brain signals that control reward and motivation

The Impact of Stress-induced KCC2 Downregulation on Mesolimbic Dopamine Signaling and Reward Processing

['FUNDING_R01'] · GEORGETOWN UNIVERSITY · NIH-11237167

This work looks at how stress reduces a brain protein called KCC2 and alters reward circuit signals in ways that may relate to depression and other stress-linked mental health problems.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorGEORGETOWN UNIVERSITY (nih funded)
Locations1 site (WASHINGTON, UNITED STATES)
Trial IDNIH-11237167 on ClinicalTrials.gov

What this research studies

Researchers will use rat models to see how stress lowers KCC2 in inhibitory (GABA) neurons in the ventral tegmental area and how that change affects dopamine signaling to the nucleus accumbens. They will record both steady (tonic) and burst (phasic) dopamine activity and measure GABA input onto dopamine neurons that project to different parts of the accumbens (core, medial shell, lateral shell). The team will link these circuit changes to altered reward processing that can drive depression-like behaviors in animals. Results will be used to identify potential molecular or circuit targets for therapies that restore normal reward signaling.

Who could benefit from this research

Good fit: People with stress-related mood problems such as major depression, PTSD, or prominent loss of pleasure (anhedonia) are the groups most likely to benefit from therapies informed by this research.

Not a fit: Patients whose problems are unrelated to stress-linked reward-circuit dysfunction (for example, purely structural brain disease or non-neuropsychiatric conditions) are unlikely to see direct benefit from this preclinical work.

Why it matters

Potential benefit: If successful, this work could point to new targets for treatments to reduce anhedonia and other stress-related symptoms by restoring inhibitory balance in reward circuits.

How similar studies have performed: Prior animal studies show that restoring KCC2 or correcting GABAergic imbalance can reverse some stress-related neural and behavioral changes, but translation to effective human treatments remains unproven.

Where this research is happening

WASHINGTON, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.